Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-01-20

Butterfly Network, Inc.

Butterfly sells semiconductor-based handheld ultrasound devices plus cloud software and AI workflow tools for point-of-care imaging.

ai hardware healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • Third Party Analyst Consensus

Summary

From handheld devices to enterprise workflow monetization

A credible path exists to reframe bedside ultrasound as a governed, auditable workflow product, not just a device sale. The upside is real but gated by enterprise proof, supplier concentration, and regulatory cadence.

Analysis

Thesis

Butterfly can compound from a handheld-probe vendor into an enterprise workflow + AI monetization layer for bedside ultrasound, with a real option on co-development/licensing that can lift revenue quality if supply-chain and regulatory gates are cleared without returning to heavy dilution.

Last Economy Alignment

Positive fit: software + data loops can make ultrasound workflow/compliance more automated as cognition becomes cheap; risk is distribution vs incumbents and regulated iteration speed.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.0x (from 5 most recent analyses)

Reasoning

The credible upside is a mix shift: more enterprise deployments where software/AI attach, fleet governance, and compliance tooling become part of the ongoing operating budget (less episodic). If the company sustains device momentum while proving repeatable enterprise ROI and expanding developer/partner monetization, the market can keep valuing it as a platform medtech (not pure hardware), even with moderate capital intensity.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The path to a higher-quality multiple runs through (1) repeatable enterprise conversion and monetization of workflow/AI, (2) avoiding renewed dilution by keeping cash use disciplined, and (3) clearing binding external gates: concentrated suppliers plus ongoing regulatory permissioning. Any stumble on guidance/runway or supply disruption can cap growth even with strong demand.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Jan-12-2026: pre-announced at least 17% YoY Q4-2025 revenue growth; reiterated audited FY2025 results and 2026 guidance timing (late February).
Jan-06-2026: announced plans to open a developer API for advanced imaging capabilities in 1H-2026, signaling increased partner/platform emphasis.
Mid-Jan-2026: management presented at the J.P. Morgan Healthcare Conference, keeping focus on chip co-development/licensing narrative.

Upgrade to Builder to also access: Future Considerations

Third Party Analyst Consensus

12-Month Price Target

$4.19

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case